DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 884 filers reported holding DANAHER CORPORATION in Q4 2013. The put-call ratio across all filers is 0.40 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,330,060 | +99495.0% | 37,606 | -3.7% | 0.41% | +3.3% |
Q2 2023 | $9,368 | -2.8% | 39,034 | +2.1% | 0.39% | -5.7% |
Q1 2023 | $9,638 | +15.2% | 38,238 | +21.3% | 0.42% | +12.1% |
Q4 2022 | $8,365 | -99.9% | 31,518 | +10.9% | 0.37% | -24.8% |
Q3 2022 | $7,344,000 | -18.0% | 28,433 | -19.6% | 0.50% | +25.6% |
Q2 2022 | $8,961,000 | -10.8% | 35,347 | +3.2% | 0.40% | +3.9% |
Q1 2022 | $10,047,000 | +15.2% | 34,253 | +29.2% | 0.38% | +21.0% |
Q4 2021 | $8,722,000 | +7.2% | 26,509 | -0.8% | 0.31% | +0.6% |
Q3 2021 | $8,137,000 | +1.8% | 26,729 | -10.2% | 0.31% | +4.7% |
Q2 2021 | $7,991,000 | +18.9% | 29,777 | -0.3% | 0.30% | +12.0% |
Q1 2021 | $6,721,000 | +1.2% | 29,860 | -3.2% | 0.27% | -13.6% |
Q3 2020 | $6,643,000 | +6.7% | 30,851 | -12.4% | 0.31% | +0.3% |
Q2 2020 | $6,226,000 | +30.9% | 35,205 | +2.5% | 0.31% | +11.2% |
Q1 2020 | $4,756,000 | +19.1% | 34,358 | +32.0% | 0.28% | +50.8% |
Q4 2019 | $3,994,000 | -7.9% | 26,021 | -13.4% | 0.18% | -15.3% |
Q3 2019 | $4,338,000 | -5.0% | 30,031 | -6.0% | 0.22% | -3.1% |
Q2 2019 | $4,565,000 | +7.9% | 31,940 | -0.3% | 0.22% | +5.7% |
Q1 2019 | $4,231,000 | +14.5% | 32,049 | -10.5% | 0.21% | -4.1% |
Q4 2018 | $3,694,000 | -2.5% | 35,826 | +2.7% | 0.22% | +17.6% |
Q3 2018 | $3,789,000 | +5.0% | 34,875 | -4.6% | 0.19% | 0.0% |
Q2 2018 | $3,607,000 | -1.9% | 36,549 | -2.7% | 0.19% | -0.5% |
Q1 2018 | $3,677,000 | +4.8% | 37,551 | -0.7% | 0.19% | -21.0% |
Q4 2017 | $3,509,000 | +4.7% | 37,803 | -3.2% | 0.24% | +36.0% |
Q3 2017 | $3,350,000 | +2.3% | 39,047 | +0.6% | 0.18% | -1.7% |
Q2 2017 | $3,276,000 | -0.0% | 38,821 | +1.3% | 0.18% | -2.2% |
Q1 2017 | $3,277,000 | +5.4% | 38,322 | -4.0% | 0.18% | +2.8% |
Q4 2016 | $3,109,000 | +15.8% | 39,937 | +16.6% | 0.18% | +11.3% |
Q3 2016 | $2,685,000 | -23.9% | 34,256 | -2.0% | 0.16% | -24.3% |
Q2 2016 | $3,529,000 | +5.5% | 34,944 | -0.9% | 0.21% | +5.5% |
Q1 2016 | $3,345,000 | -4.2% | 35,265 | -6.2% | 0.20% | -3.4% |
Q4 2015 | $3,492,000 | +92.6% | 37,597 | +76.7% | 0.21% | +87.3% |
Q3 2015 | $1,813,000 | +78.1% | 21,280 | +78.9% | 0.11% | +93.0% |
Q2 2015 | $1,018,000 | +3.5% | 11,896 | +2.7% | 0.06% | +5.6% |
Q1 2015 | $984,000 | -8.3% | 11,584 | -7.4% | 0.05% | -6.9% |
Q4 2014 | $1,073,000 | +20.6% | 12,509 | +6.8% | 0.06% | +16.0% |
Q3 2014 | $890,000 | +4.3% | 11,708 | +8.1% | 0.05% | +4.2% |
Q2 2014 | $853,000 | +5.6% | 10,828 | +0.5% | 0.05% | +4.3% |
Q1 2014 | $808,000 | -0.5% | 10,778 | +2.4% | 0.05% | 0.0% |
Q4 2013 | $812,000 | -1.3% | 10,528 | -11.3% | 0.05% | -9.8% |
Q3 2013 | $823,000 | -33.2% | 11,868 | -39.0% | 0.05% | -36.2% |
Q2 2013 | $1,232,000 | – | 19,468 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |